Vivos Therapeutics (NASDAQ:VVOS) just reported results for the second quarter of 2024.
- Vivos Therapeutics reported earnings per share of -60 cents. This was above the analyst estimate for EPS of -$1.05.
- The company reported revenue of $4.05 million.
- This was 12.61% better than the analyst estimate for revenue of $3.60 million.